Moderna-Merck Cancer Vaccine Breakthrough Marks New Era in Personalised Treatment

A breakthrough in cancer treatment has been announced by Moderna and Merck & Co., with their personalised mRNA-based cancer vaccine delivering significant results in a late-stage melanoma trial. This achievement marks a major milestone for the companies, as it is the first time an mRNA-based cancer vaccine has demonstrated success in a large-scale study.

The vaccine reduced the rate of melanoma recurrence in the final-stage clinical trial, with investors and cancer researchers welcoming the announcement as a potentially significant turning point for the field. Moderna shares surged 177% on the day the results were reported, with the companies yet to disclose the full details or magnitude of the benefit.

The technology uses mRNA to instruct cells to produce fragments of mutated proteins found in a patient's tumour, training the immune system to recognise and attack cancer cells. This approach is particularly suited to patients who have undergone surgery and are at high risk of recurrence.

While important questions remain unanswered, including the size of the reduction in recurrence and whether patients receiving the vaccine will live longer, the success has encouraged wider efforts to develop mRNA-based cancer treatments. Moderna and Merck are testing their personalised approach in other cancers, including lung, bladder, and kidney tumours.